Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 114 matching drugs for LDLR — including drugs targeting any of its 156 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
porfimer sodium LDLR Direct 1
porfimer sodium, adjuvant therapy, conventional surgery LDLR Direct 1
porfimer sodium, endoscopic ultrasonography, photodynamic therapy, gemcitabine hydrochloride LDLR Direct 1
olaparib PARP1 SSL via PARP1 yes 1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CSK SSL via CSK 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CSK SSL via CSK 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC3 SSL via HDAC3 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine POLA1 SSL via POLA1 2
pembrolizumab, guadecitabine, mocetinostat HDAC3 SSL via HDAC3 2
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC3 SSL via HDAC3 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC3 SSL via HDAC3 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CSK SSL via CSK 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes POLA1 SSL via POLA1 1
atorvastatin, temozolomide, radiotherapy HMGCR SSL via HMGCR 1
autologous mesothelin-specific tcr-t cells, cyclophosphamide, fludarabine, bendamustine POLA1 SSL via POLA1 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab HDAC3 SSL via HDAC3 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus POLA2 SSL via POLA2 1
bendamustine, biopsy, biospecimen collection, computed tomography, cyclophosphamide, echocardiography, fludarabine, leukapheresis, magnetic resonance imaging, multigated acquisition scan, positron emission tomography, t-cell receptor-engineered t-cells POLA1 SSL via POLA1 1
bevacizumab, dasatinib, placebo CSK SSL via CSK 1
bevacizumab, temozolomide, vorinostat HDAC3 SSL via HDAC3 1
busulfan, anti-thymocyte globulin, fludarabine, cyclosporine, mycophenolate mofetil POLA1 SSL via POLA1 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor HDAC3 SSL via HDAC3 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin HSPA5 SSL via HSPA5 1
chemotherapy, cladribine, radiation therapy POLA1 SSL via POLA1 1
chemotherapy, cladribine, radiation therapy POLE3 SSL via POLE3 1
cyclophosphamide, fludarabine, aldesleukin, anti-hcd70 car transduced pbl POLA1 SSL via POLA1 1
cyclophosphamide, fludarabine, mutant kras g12v-specific tcr transduced autologous t cells, anti-pd-1 monoclonal antibody POLA1 SSL via POLA1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride CSK SSL via CSK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method CSK SSL via CSK 1
dasatinib, laboratory biomarker analysis, physiologic testing CSK SSL via CSK 1
dasatinib, mfolfox6 CSK SSL via CSK 1
dasatinib, pharmacological study CSK SSL via CSK 1
dasatinib, temozolomide, placebo, radiation therapy CSK SSL via CSK 1
dimethyl fumarate, temozolomide, radiation therapy KEAP1 SSL via KEAP1 1
disulfiram, copper, alkylating agents GPI SSL via GPI 1
disulfiram, copper, alkylating agents HSPA5 SSL via HSPA5 1
disulfiram, copper, alkylating agents P4HB SSL via P4HB 1
durvalumab, tazemetostat EZH2 SSL via EZH2 1
e7 tcr cells, aldesleukin, fludarabine, cyclophosphamide POLA1 SSL via POLA1 1
epidermal growth factor receptor(egfrv)iii chimeric antigen receptor (car) transduced pbl, aldesleukin, fludarabine, cyclophosphamide POLA1 SSL via POLA1 1
fludarabine, cyclophosphamide, ima101 product, recombinant human interleukin-2, imadetect, atezolizumab POLA1 SSL via POLA1 1
ft500, nivolumab, pembrolizumab, atezolizumab, cyclophosphamide, fludarabine, il-2 POLA1 SSL via POLA1 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff HDAC3 SSL via HDAC3 1
ibrutinib, fludarabine POLA1 SSL via POLA1 1
irinotecan, cisplatin, simvastatin HMGCR SSL via HMGCR 1
kras tcr-transduced pbl, aldesleukin, fludarabine, cyclophosphamide POLA1 SSL via POLA1 1
laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat HDAC3 SSL via HDAC3 1
medical cannabis HMGCR SSL via HMGCR 1
mycophenolate mofetil, tacrolimus, post-transplant cyclophosphamide, total body irradiation, hematopoietic cell transplant, jsp191, cyclophosphamide, fludarabine POLA1 SSL via POLA1 1
nabiximols, temozolomide, nabiximols-matched placebo CYP3A5 SSL via CYP3A5 1
nabiximols, temozolomide, nabiximols-matched placebo HMGCR SSL via HMGCR 1
pembrolizumab, vorinostat, temozolomide, radiotherapy HDAC3 SSL via HDAC3 1
recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine POLA2 SSL via POLA2 1
rosuvastatin HMGCR SSL via HMGCR yes 1
tc-510, fludarabine, cyclophosphamide POLA1 SSL via POLA1 1
tc-n201 cells, il-2, fludarabine, cyclophosphamide, nab-paclitaxel POLA1 SSL via POLA1 1
tcr-t cells, fludarabine, cyclophosphamide capsules, albumin-bound paclitaxel, il-2 POLA1 SSL via POLA1 1
total body irradiation (tbi), thiotepa, cyclophosphamide, busulfan, melphalan, fludarabine POLA1 SSL via POLA1 1
trop2-car-nk, cyclophosphamide, fludarabine POLA1 SSL via POLA1 1
tumor infiltrating lymphocytes (til), cyclophosphamid, fludarabine, interleukin-2, pembrolizumab POLA1 SSL via POLA1 1
tumor infiltrating lymphocytes (til), cyclophosphamide, fludarabine, interleukin-2, pembrolizumab POLA1 SSL via POLA1 1
vorinostat, bevacizumab HDAC3 SSL via HDAC3 1
vorinostat, bevacizumab, irinotecan HDAC3 SSL via HDAC3 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis HDAC3 SSL via HDAC3 1
vorinostat, conventional surgery HDAC3 SSL via HDAC3 1
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study HDAC3 SSL via HDAC3 1
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration HDAC3 SSL via HDAC3 1
vorinostat, therapeutic conventional surgery, bortezomib HDAC3 SSL via HDAC3 1
young til, aldesleukin, cyclophosphamide, fludarabine, pembrolizumab (keytruda) POLA1 SSL via POLA1 1
atorvastatin HMGCR SSL via HMGCR yes 0
atorvastatin calcium HMGCR SSL via HMGCR yes 0
belinostat HDAC3 SSL via HDAC3 yes 0
cerivastatin HMGCR SSL via HMGCR yes 0
cerivastatin sodium HMGCR SSL via HMGCR yes 0
clofarabine POLA1 SSL via POLA1 yes 0
cobicistat CYP3A5 SSL via CYP3A5 yes 0
cytarabine POLA1 SSL via POLA1 yes 0
dextrothyroxine THRB SSL via THRB yes 0
dextrothyroxine sodium THRB SSL via THRB yes 0
dimethyl fumarate KEAP1 SSL via KEAP1 yes 0
diroximel fumarate KEAP1 SSL via KEAP1 yes 0
fludarabine phosphate POLA1 SSL via POLA1 yes 0
fluvastatin HMGCR SSL via HMGCR yes 0
fluvastatin sodium HMGCR SSL via HMGCR yes 0
gemcitabine POLA1 SSL via POLA1 yes 0
gemcitabine hydrochloride POLA1 SSL via POLA1 yes 0
levothyroxine THRB SSL via THRB yes 0
levothyroxine sodium THRB SSL via THRB yes 0
liothyronine THRB SSL via THRB yes 0
liothyronine sodium THRB SSL via THRB yes 0
lomitapide P4HB SSL via P4HB yes 0
lomitapide mesylate P4HB SSL via P4HB yes 0
lovastatin HMGCR SSL via HMGCR yes 0
monomethyl fumarate KEAP1 SSL via KEAP1 yes 0
nelarabine POLA1 SSL via POLA1 yes 0
niraparib PARP1 SSL via PARP1 yes 0
niraparib tosylate PARP1 SSL via PARP1 yes 0
panobinostat HDAC3 SSL via HDAC3 yes 0
panobinostat lactate HDAC3 SSL via HDAC3 yes 0
pitavastatin HMGCR SSL via HMGCR yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.